Compare Bristol-Myers Squibb Co (BMY) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

BRK.B trades at $490.00, down 1.37% on the day. The technical picture shows a bullish moving average signal but neutral oscillators, with immediate support at $489 and resistance at $495. Analyst consensus is bullish with 57% buy ratings and no sell recommendations. The stock's valuation metrics are not provided in the current dataset.

The outlook is cautiously positive based on analyst sentiment and technical positioning near support. Key risks include market volatility and the company's exposure to broad economic cycles. The absence of current fundamental data necessitates direct review of Berkshire Hathaway's latest SEC filings for a complete investment picture.